Portal de Periódicos da CAPES

Universal thromboprophylaxis in ovarian cancer patients before and after surgery?

2023; Elsevier BV; Volume: 176; Linguagem: Inglês

10.1016/j.ygyno.2023.08.003

1095-6859

Sara Moufarrij, Laura J. Havrilesky, Elizabeth L. Jewell,

Acute Myocardial Infarction Research

Patients with ovarian cancer have one of the highest incidences of venous thromboembolic events (VTEs) among patients with solid tumors, with overall rates ranging from 25 to 38% [ 1 Metcalf R.L. Fry D.J. Swindell R. et al. Thrombosis in ovarian cancer: a case control study. Br. J. Cancer. Mar 4 2014; 110: 1118-1124https://doi.org/10.1038/bjc.2014.3 Crossref PubMed Scopus (32) Google Scholar , 2 Walker A.J. Card T.R. West J. Crooks C. Grainge M.J. Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases. Eur. J. Cancer. 2013; 49 (2013/04/01/): 1404-1413https://doi.org/10.1016/j.ejca.2012.10.021 Abstract Full Text Full Text PDF PubMed Scopus (331) Google Scholar , 3 Blom J.W. Vanderschoot J.P. Oostindiër M.J. Osanto S. van der Meer F.J. Rosendaal F.R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost. Mar 2006; 4: 529-535https://doi.org/10.1111/j.1538-7836.2006.01804.x Abstract Full Text Full Text PDF PubMed Scopus (518) Google Scholar ]. Cancer-associated thrombosis is a major cause of morbidity and mortality in oncologic patients and has particularly important implications in ovarian cancer, including requirement for therapeutic anticoagulation during a time of variable hematologic counts, possible delays in cytoreductive surgery, reduction in quality of life, and higher cost of care [ [4] Black K.A. Ghosh S. Singh N. Chu P. Pin S. Venous thromboembolism in patients receiving neoadjuvamt chemotherapy for advanced ovarian cancer and impact on survival. J. Obstet. Gynaecol. Can. 2021; 43: 1380-1387 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar , [5] Levine M. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb. Haemost. 1997; 78 PubMed Google Scholar ]. Data suggest that cancer patients with VTE have 2-fold greater mortality compared to cancer patients without VTE, even after adjusting for stage [ [6] Carrier M. Abou-Nassar K. Mallick R. Tagalakis V. Shivakumar S. Schatter A. Apixaban to prevent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2018; 380: 711-719 Crossref PubMed Scopus (519) Google Scholar , [7] Salinaro J. McQuillen K. Stemple M. Boccaccio R. Ehrisman J. Lorenzo A. Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2020; 30: 491-497 Crossref PubMed Scopus (16) Google Scholar ].